Search results for: Real World Evidence (RWE)
Filter search results
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
…of investment in evidence collection, matter. If the innovator expects to receive a value-based price that reflects the value of the health gain to the payer, then its evidence generation…
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
4 January 2019
The aim of this paper is to provide an overview of the issues that might limit comparability of PRO data and to highlight some of the evidence that exists on…
Innovation in Oncology: Real Option Value and Path Dependence
29 April 2014
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward innovation through the pricing…
Does the New CBO Report Change Anything?
15 September 2021
…fails to adequately represent the reality of biopharmaceutical investing. An overly simplified model that does not approximate reality may have some academic interest, but it cannot be reliably used to…
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…acceptability (e.g. patient attitudes and cultural factors). Vaccine uptake rhetoric vs. the reality, and the 5 A’s framework The discrepancy between high level targets, and the reality of implementation challenges,…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…will provide to accelerate and advance the collection and use of real-world evidence. After 10 or so years on the market, rigorous data will be expected on the outcomes achieved…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…the grounds of unmet therapeutic need, therapeutic added value, and quality of the evidence. All appraisals are published on the AIFA’s website. Recently published evidence showed that the main drivers…
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Dalia Dawoud, Pillar Pinilla-Dominguez, Caroline Bregman, and Hania El Banhawi…
Economic Evaluation and Develop Medicines in the Development of Medicines
1 April 1988
…generate more high quality evidence on the costs and benefits of medicines? How should such evidence be interpreted and used by health care decision makers? What methodological uncertainties remain and…